MORPHIC HOLDING INC (MORF)
US61775R1059 - Common Stock
Taking everything into account, MORF scores 3 out of 10 in our fundamental rating. MORF was compared to 587 industry peers in the Biotechnology industry. While MORF has a great health rating, there are worries on its profitability. MORF is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year MORF has reported negative net income.
In the past year MORF has reported a negative cash flow from operations.
In the past 5 years MORF always reported negative net income.
MORF had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MORF has a Return On Assets of -23.62%. This is in the better half of the industry: MORF outperforms 77.44% of its industry peers.
The Return On Equity of MORF (-24.30%) is better than 83.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.62% | ||
| ROE | -24.3% | ||
| ROIC | N/A |
ROA(3y)-19.83%
ROA(5y)-19.11%
ROE(3y)-22.37%
ROE(5y)-25.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for MORF so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MORF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MORF has more shares outstanding
Compared to 5 years ago, MORF has more shares outstanding
MORF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
MORF has an Altman-Z score of 50.04. This indicates that MORF is financially healthy and has little risk of bankruptcy at the moment.
MORF has a better Altman-Z score (50.04) than 97.44% of its industry peers.
MORF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 50.04 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 38.17 indicates that MORF has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 38.17, MORF belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.
A Quick Ratio of 38.17 indicates that MORF has no problem at all paying its short term obligations.
MORF has a better Quick ratio (38.17) than 98.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 38.17 | ||
| Quick Ratio | 38.17 |
3. Growth
3.1 Past
The earnings per share for MORF have decreased strongly by -120.75% in the last year.
MORF shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
Measured over the past years, MORF shows a very negative growth in Revenue. The Revenue has been decreasing by -31.12% on average per year.
EPS 1Y (TTM)-120.75%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-0.64%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-77.37%
Revenue growth 5Y-31.12%
Revenue growth Q2Q-100%
3.2 Future
MORF is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.11% yearly.
The Revenue is expected to grow by 213.82% on average over the next years. This is a very strong growth
EPS Next Y-13.19%
EPS Next 2Y-10.93%
EPS Next 3Y-8.75%
EPS Next 5Y0.11%
Revenue Next Year-50.42%
Revenue Next 2Y-18.69%
Revenue Next 3Y-7.43%
Revenue Next 5Y213.82%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MORF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MORF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as MORF's earnings are expected to decrease with -8.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.93%
EPS Next 3Y-8.75%
5. Dividend
5.1 Amount
MORF does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MORPHIC HOLDING INC
NASDAQ:MORF (5/17/2024, 7:14:11 PM)
After market: 29.23 0 (0%)29.23
-3.22 (-9.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.46B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.62% | ||
| ROE | -24.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 38.17 | ||
| Quick Ratio | 38.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-120.75%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-13.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3Y-77.37%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y